Effect of plasma exchange combined with continuous renal replacement therapy on the prognosis of patients with HBV-related acute-on-chronic liver failure and acute kidney injury

Yao YunHai; Gan JianHe; Zhao WeiFeng

doi:10.3969/j.issn.1001-5256.2019.05.026

Volume 35 Issue 5

May 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(5): 1065-1069

PDF( 1970 KB)

Effect of plasma exchange combined with continuous renal replacement therapy on the prognosis of patients with HBV-related acute-on-chronic liver failure and acute kidney injury

DOI: 10.3969/j.issn.1001-5256.2019.05.026

Department of Infectious Diseases & Liver Intensive Care Unit, The First Affiliated Hospital of Soochow University

Research funding:

Received Date: 2018-11-23
Published Date: 2019-05-20

Abstract

Abstract

Objective To investigate the effect of plasma exchange ( PE) combined with continuous renal replacement therapy ( CRRT) on the prognosis of patients with HBV-related acute-on-chronic liver failure ( ACLF) and acute kidney injury ( AKI) . Methods A retrospective analysis was performed for the clinical data of 198 HBV-ACLF-AKI patients who were admitted to The First Affiliated Hospital of Soochow University from August 1, 2013 to August 1, 2017. According to the technique of blood purification, they were divided into pharmacotherapy group ( group A with 68 patients) , PE group ( group B with 56 patients) , and PE + CRRT group ( group C with 74 patients) .Related clinical data on admission were collected, including sex, age, biochemical parameters after blood purification ( total bilirubin, albumin, serum sodium, international normalized ratio, white blood cell count, platelet count, and hematocrit) , common complications, and blood purification method. Creatinine clearance rate ( CCR) , estimated glomerular filtration rate ( eGFR) , and MELD combined with serum sodium concentration ( MELD-Na) were calculated before and after treatment. A one-way analysis of variance was used for comparison of normally distributed continuous data between three groups; the paired t-test was used for comparison within one group before and after treatment, and the two samples t-test was used for comparison between groups. The Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between three groups; the paired samples Wilcoxon signed rank test was used for comparison within one group before and after treatment, and the Mann-Whitney U test was used for comparison between groups. The chi-square test was used for comparison of categorical data between three groups. The Cox proportional-hazards regression model was used to investigate the influencing factors for survival time and outcome. Results Before treatment, there were significant differences between the three groups in sex, age, blood biochemical parameters, eGFR, CCR, complications, and MELD-Na ( all P > 0. 05) . Groups B and C had significant increases in eGFR and CCR and a significant reduction in MELD-Na after treatment ( group B: Z =-2. 81, Z =-3. 67, t = 6. 07, all P < 0. 05;group C: Z =-5. 81, Z =-4. 05, t =-6. 90, all P < 0. 05) , and there were no significant differences in eGFR, CCR, and MELD-Na between groups B and C after treatment ( all P > 0. 05) . The regression analysis showed that eGFR, CCR, and MELD-Na after blood purification were influencing factors for the survival indices of ACLF-AKI patients ( all P < 0. 05) . The risk of death and cumulative risk gradually increased over the time of hospitalization. Conclusion PE alone or in combination with CRRT can significantly improve the renal function of ACLF-AKI patients, but the combination treatment has no obvious advantages. The improvement in renal function after blood purification directly affects the prognosis of ACLF-AKI patients, and the risk of death and cumulative risk gradually increase over the time of hospitalization.
- liver failure,
- hepatitis b virus,
- renal insufficiency,
- plasma exchange,
- renal replacement therapy,
- prognosis

FullText(HTML)

References(25)

References

[1] BERNAL W, JALAN R, QUAGLIA A, et al. Acute-on-chronic liver failure[J]. Lancet, 2015, 386 (10003) :1576-1587.

[2] JIANG QQ, HAN MF, MA K, et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis[J]. World J Gastroenterol, 2018, 24 (21) :2300-2310.

[3] YANG XL, ZHOU Q, ZHENG CH, et al. Analysis of plasma exchange and continuous blood purification in treatment of patients with hepatitis B liver failure[J]. J Prac Hepatol, 2018 (3) :469-470. (in Chinese) 杨晓玲, 周强, 郑春华, 等.血浆置换联合连续性血液净化治疗肝衰竭患者短期疗效观察[J].实用肝脏病杂志, 2018 (3) :469-470.

[4] HAN LF, JIN HX. Hemoperfusion combined with continuous renal replacement therapy in the treatment of acute paraquat poisoning[J]. Trauma Crit Med, 2017, 5 (4) :224-227. (in Chinese) 韩龙飞, 金红旭.血液灌流联合持续肾替代疗法治疗急性百草枯中毒疗效分析[J].创伤与急危重病医学, 2017, 5 (4) :224-227.

[5] GUO Y, SUN Y, YU HY, et al. Continuous renal replacement therapy for senile chronic renal insufficiency combined with multiple organ dysfunction[J]. Clin J Med Offic, 2017, 45 (2) :184-186. (in Chinese) 郭阳, 孙岩, 于慧颖, 等.连续性肾替代疗法治疗老年慢性肾功能不全合并多器官功能障碍效果分析[J].临床军医杂志, 2017, 45 (2) :184-186.

[6] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2012 version) [J]. Chin J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华临床感染病杂志, 2012, 5 (6) :321-327.

[7] HUELIN P, PIANO S, SOLA E, et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure[J]. Clin Gastroenterol Hepatol, 2017, 15 (3) :438-445.

[8] ZANG H, LIU F, LIU H, et al. Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis[J]. Hepatol Int, 2016, 5 (10) :807-818.

[9] FAGUNDES C, BARRETO R, GUEVARA M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis[J]. J Hepatol, 2013, 59 (3) :474-481.

[10] NAKAMURA T, USHIYAMA C, SUZUKI S, et al. Effect of plasma exchange on serum tissue inhibitor of metalloproteinase 1 and cytokine concentrations in patients with fulminant hepatitis[J].Blood Purif, 2000, 18 (1) :50-54.

[11] di CAMPLI C, SANTORO MC, GASPARI R, et al. Catholic university experience with molecular adsorbent recycling system in patients with severe liver failure[J]. Transplant Proc, 2005, 37 (6) :2547-2550.

[12] EDMARK C, MCPHAIL MJ, BELL M, et al. Li Fe:A liver injury score to predict outcome in critically ill patients[J]. Intensive Care Med, 2016, 3 (42) :361-369.

[13] WENDON J, CORDOBA J, DHAWAN A, et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure[J]. J Hepatol, 2017, 66 (5) :1047-1081.

[14] LIU Y, KANG YZ, XIA WZ, et al. Artificial and bioartificial liver support systems for acute and acute-on-chronic liver failure:A meta-analysis[J]. J Southern Med Univ, 2009, 29 (8) :1529-1532.

[15] JIANG H, BAI XF. Research advances in acute liver failure[J]. J Clin Hepatol, 2018, 34 (9) :1824-1831. (in Chinese) 姜泓, 白雪帆.急性肝衰竭研究进展[J].临床肝胆病杂志, 2018, 34 (9) :1824-1831.

[16] WU D, SUN Z, LIU X, et al. HINT:A novel prognostic model for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Aliment Pharmacol Ther, 2018, 48 (7) :750-760.

[17] ZHOU XD, CHEN QF, SUN DQ, et al. Remodeling the model for end-stage liver disease for predicting mortality risk in critically ill patients with cirrhosis and acute kidney injury[J]. Hepatol Commun, 2017, 1 (8) :748-756.

[18] GAMEIRO J, AGAPITO FONSECA J, MONTEIRO DIAS J, et al. Prediction of acute kidney injury in cirrhotic patients:A new score combining renal, liver and inflammatory markers[J]. Int J Nephrol Renovasc Dis, 2018, 11:149-154.

[19] BISELLI M, DALL'AGATA M, GRAMENZI A, et al. A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score<[J]. Liver Int, 2015, 35 (1) :184-191.

[20] MAIWALL R, KUMAR S, CHANDEL SS, et al. AKI in patients with acute on chronic liver failure is different from acute decompensation of cirrhosis[J]. Hepatol Int, 2015, 9 (4) :627-639.

[21] CHEN N, CHEN X, DING X, et al. Analysis of the high incidence of acute kidney injury associated with acute-on-chronic liver failure[J]. Hepatol Int, 2018, 12 (3) :262-268.

[22] MAIWALL R, KUMAR G, BHARADW A, et al. AKI persistence at 48 h predicts mortality in patients with acute on chronic liver failure[J]. Hepatol Int, 2017, 11 (6) :529-539.

[23] BELCHER JM, SANYAL AJ, PEIXOTO AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury[J]. Hepatology, 2014, 60 (2) :622-632.

[24] ANNICCHIARICO BE, AVOLIO AW, SICILIANO M, et al. Acute decompensation and absence of brain and kidney dysfunction predict long-term efficacy of plasma exchange in hyper-bilirubinemic cirrhotic patients awaiting liver transplantation[J]. Transplant Proc, 2008, 40 (6) :1929-1931.

[25] OSTAPOWICZ G, LEE WM. Acute hepatic failure:A Western perspective[J]. J Gastroenterol Hepatol, 2000, 15 (5) :480-488.

Relative Articles

[1]	Ke SHI, Qun ZHANG, Xianbo WANG, Ying FENG. Effect of intestinal flora and metabolites on the development and progression of acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2025, 41(3): 568-573. doi: 10.12449/JCH250327
[2]	Viral Hepatitis Group of Professional Committee of Liver Disease （combined traditional Chinese and western medicine） of Chinese Research Hospital Association, Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases. Guidelines for fecal microbiota transplantation therapy in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2025, 41(3): 424-431. doi: 10.12449/JCH250306
[3]	Xiaoming WU, Qiang HE, Linyi HOU, Yan HU, Xiaofang ZHEN, Jing HAO, Yan SHENG. Effect of Yudantong decoction on intestinal flora and intestinal barrier function in mice with cholestasis induced by α-naphthyl isothiocyanate[J]. Journal of Clinical Hepatology, 2023, 39(4): 864-875. doi: 10.3969/j.issn.1001-5256.2023.04.018
[4]	Hongkai XU, Chunfu WANG, Ye ZHANG, Jianqi LIAN. Role of fecal microbiota transplantation in chronic liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(9): 2237-2243. doi: 10.3969/j.issn.1001-5256.2023.09.031
[5]	Guirong CHEN, Minggang WANG, Huaming LIN, Huiping YAN, Xiufeng WANG. Changes and pathogenic mechanism of intestinal flora in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(8): 1992-1998. doi: 10.3969/j.issn.1001-5256.2023.08.034
[6]	Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis： Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
[7]	Yixin HOU, Qun ZHANG, Yuyong JIANG, Hao YU, Yuying YANG, Xianbo WANG. Effect of Liangxue Jiedu decoction on intestinal flora in patients with hepatitis B virus-related acute-on-chronic liver failure: An analysis based on high-throughput sequencing[J]. Journal of Clinical Hepatology, 2022, 38(6): 1280-1287. doi: 10.3969/j.issn.1001-5256.2022.06.013
[8]	Fuchun WANG, Ziyi LI, Wanjie ZHANG, Xiaorong MAO, Junfeng LI. The significance of gut microbiota in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(7): 1667-1670. doi: 10.3969/j.issn.1001-5256.2022.07.040
[9]	Transplantation Immunology Committee of Branch of Organ Transplantation Physician of Chinese Medical Doctor Association, Organ Transplant Rehabilitation Committee of China Association Rehabilitation Medicine, Branch of Organ Transplantation Physician of Guangdong Medical Doctor Association. Expert consensus on liver transplantation perioperative evaluation and rehabilitation for acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(12): 2701-2708. doi: 10.3969/j.issn.1001-5256.2022.12.005
[10]	Hui DENG, Bin ZHANG, Bin ZHU, Zhayier DILIHUMAER, Weixian WANG, Chunxia GUO, Dongliang YANG, Xin ZHENG, Junzhong WANG, Baoju WANG. Research advances in the role of gut microbiota in chronic hepatitis B, chronic hepatitis C, and related liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1143-1147. doi: 10.3969/j.issn.1001-5256.2022.05.035
[11]	Mingyin MAN, Nana LI, Yue BU, Kaijiang YU. Influence of mitochondria-targeted antioxidant SS-31 on acute liver injury in a mouse model of sepsis[J]. Journal of Clinical Hepatology, 2022, 38(2): 392-396. doi: 10.3969/j.issn.1001-5256.2022.02.025
[12]	Xujuan LUO, Xue BAI, Zenghui LI, Fan LIU, Hao TANG, Ruoxin LI, Guodong YANG. Clinical effect of fecal microbiota transplantation versus the traditional Chinese medicine Rheum officinale in a rat model of hyperlipidemic acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(12): 2767-2773. doi: 10.3969/j.issn.1001-5256.2022.12.016
[13]	Ziwei GUO, Jiaxin ZHANG, Shuo LI, Xiaobin LI, Shun ZHU, Qian JIN, Xiaoke LI, Yongan YE. Research advances in intestinal flora and the development and prognosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(5): 1137-1142. doi: 10.3969/j.issn.1001-5256.2022.05.034
[14]	Lingyan XIAO, Awen XING, Shanzhong TAN. Research advances in the association between liver failure and intestinal barrier injury[J]. Journal of Clinical Hepatology, 2021, 37(11): 2710-2714. doi: 10.3969/j.issn.1001-5256.2021.11.049
[15]	Yanyan CHEN, Yanmei LAN, Minggang WANG, Dewen. MAO. Mechanism of action of bile acid-farnesoid X receptor-intestinal microecological axis in the development of liver failure and liver regeneration[J]. Journal of Clinical Hepatology, 2021, 37(2): 480-484. doi: 10.3969/j.issn.1001-5256.2021.02.049
[16]	Menghao LI, Kai LI, Shihao TANG, Zhengyu WANG, Wengang GUO, Zhanxin YIN, Guohong HAN. Changes in gut microbiota after transjugular intrahepatic portosystemic shunt in cirrhotic patients with mild hepatic encephalopathy in different prognosis groups[J]. Journal of Clinical Hepatology, 2021, 37(2): 326-330. doi: 10.3969/j.issn.1001-5256.2021.02.016
[17]	Li HongShan, Hu YiYang. Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 14-18. doi: 10.3969/j.issn.1001-5256.2020.01.002
[18]	Huang YunYi, Liu Yao, Zhang Qun, Shi Ke, Wang XianBo. Association of intestinal microecology with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2020, 36(4): 912-914. doi: 10.3969/j.issn.1001-5256.2020.04.045
[19]	Huang Qian, Zhang HaiBo, Li JingTao, Wei HaiLiang, Yan ShuGuang, Hui Yi, Chang ZhanJie. Research advances in the mechanism of action of intestinal microecology in intrahepatic cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2355-2359. doi: 10.3969/j.issn.1001-5256.2019.10.050
[20]	Zheng Wei, Zhang YongHong, Zhao Yan. Role of intestinal microflora in the pathogenesis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1613-1615. doi: 10.3969/j.issn.1001-5256.2019.07.041

Supplements(0)

Cited By

Cited by

Periodical cited type(9)

1.	刘韦，白浪. 慢加急性肝衰竭动物模型研究现状. 临床肝胆病杂志. 2024(01): 187-192 . 本站查看
2.	陈然，王帅，高扬，杨志琴，徐严. HBV相关慢加急性肝衰竭合并脓毒症的诊疗进展. 肝脏. 2024(07): 867-870 .
3.	刘扬，洪文，黄克林，杨博，刘亚坡，路明. 粪菌移植对顽固性便秘小鼠的肠道菌群和肠道动力以及TLR4/NF-κB通路蛋白的影响. 现代生物医学进展. 2024(16): 3020-3024 .
4.	于丹丹，刘亚坡，洪文，杨博，张媛. 粪菌移植对顽固性便秘患者肠道功能、免疫功能及炎症反应的改善效果. 结直肠肛门外科. 2024(05): 578-583 .
5.	阮浩龙，王宁，于鸿浩，岳鹏鹏. 基于基因编辑技术研究特定基因对小鼠肠道微生物的影响. 中国医学工程. 2024(11): 44-49 .
6.	徐洪凯，汪春付，张野，连建奇. 粪菌移植在慢性肝病治疗中的应用. 临床肝胆病杂志. 2023(09): 2237-2243 . 本站查看
7.	周荃，蔡春琳，李金强. 肠-肝轴：肠道微生物稳态与肝细胞癌. 临床肝胆病杂志. 2023(11): 2710-2717 . 本站查看
8.	周宜，刘晓琴，吴学敏，张浩，王海琴，王红亮，孟祥龙. 乳香及其炮制品对葡聚糖硫酸钠诱导小鼠炎症性肠病的保护作用. 现代药物与临床. 2022(07): 1432-1438 .
9.	刘蕾，高越颖，郭琳，邱立朋，李会，耿燕. 酒精性肝损伤保护的药理实验教学设计. 实验室研究与探索. 2022(05): 238-243 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1640) PDF downloads(291)

Effect of plasma exchange combined with continuous renal replacement therapy on the prognosis of patients with HBV-related acute-on-chronic liver failure and acute kidney injury

DOI: 10.3969/j.issn.1001-5256.2019.05.026

Abstract

References

Relative Articles

Cited by

Periodical cited type(9)

Other cited types(2)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content